Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024 [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
Jaguar Health, Inc. (JAGX)
US:NASDAQ Investor Relations:
jaguarhealth.gcs-web.com/investor-overview
Company Research
Source: Yahoo! Finance
team, patient advocates, and leading oncology experts on cancer therapy-related diarrhea (CTD) and oral mucositis Cancer patients with diarrhea are 40% more likely to discontinue their therapy, and up to 40% of cancer patients experience the painful side effect of oral mucositis SAN FRANCISCO, CA / ACCESSWIRE / June 12, 2024 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar") today announced that it will hold an investor webcast on or before July 23, 2024 to provide results for the company's pivotal phase 3 OnTarget trial of crofelemer for prophylaxis of diarrhea in adult cancer patients with solid tumors receiving targeted therapy, with or without standard chemotherapy. The webcast, which will provide updates on Jaguar's advancing cancer supportive care portfolio, will include members of Jaguar's scientific team, patient advocates, and leading oncology experts on two of the most common and intolerable side effects of cancer therapy: CTD and oral mucositis. "Patients are the heart of
Show less
Read more
Impact Snapshot
Event Time:
JAGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JAGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JAGX alerts
High impacting Jaguar Health, Inc. news events
Weekly update
A roundup of the hottest topics
JAGX
News
- Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Regains Compliance with Nasdaq's Bid Price RequirementAccesswire
- Jaguar Health, Inc. (NASDAQ: JAGX) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders [Yahoo! Finance]Yahoo! Finance
- Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of StockholdersAccesswire
JAGX
Sec Filings
- 6/26/24 - Form 8-K
- 6/21/24 - Form 8-K
- 6/10/24 - Form 8-K
- JAGX's page on the SEC website